165 related articles for article (PubMed ID: 35930252)
21. Factors predicting requirement of high-dose transdermal fentanyl in opioid switching from oral morphine or oxycodone in patients with cancer pain.
Kanbayashi Y; Hosokawa T; Okamoto K; Fujimoto S; Konishi H; Otsuji E; Yoshikawa T; Takagi T; Miki T; Taniwaki M
Clin J Pain; 2011 Oct; 27(8):664-7. PubMed ID: 21471811
[TBL] [Abstract][Full Text] [Related]
22. Opioid rotation in the treatment of joint pain. A review of 67 cases.
Grilo RM; Bertin P; Scotto di Fazano C; Coyral D; Bonnet C; Vergne P; Treves R
Joint Bone Spine; 2002 Oct; 69(5):491-4. PubMed ID: 12477234
[TBL] [Abstract][Full Text] [Related]
23. Dose conversion in opioid rotation from continuous intravenous infusion of morphine hydrochloride injection to fentanyl patch in the management of cancer pain.
Kawano C; Hirayama T; Kuroyama M
Yakugaku Zasshi; 2011 Mar; 131(3):463-7. PubMed ID: 21372544
[TBL] [Abstract][Full Text] [Related]
24. [Opioid switch and change of route of administration in cancer patients treated by morphine].
Michenot N; Rostaing S; Baron L; Faure S; Jovenin N; Hubault P; Delorme T; Collin E; Filbet M; Chvetzoff G; Delorme C; Minello C; Magnet M; Ammar D; Krakowski I; Poulain P
Bull Cancer; 2018 Nov; 105(11):1052-1073. PubMed ID: 30274680
[TBL] [Abstract][Full Text] [Related]
25. Patient-reported utilization patterns of fentanyl transdermal system and oxycodone hydrochloride controlled-release among patients with chronic nonmalignant pain.
Ackerman SJ; Mordin M; Reblando J; Xu X; Schein J; Vallow S; Brennan M
J Manag Care Pharm; 2003; 9(3):223-31. PubMed ID: 14613465
[TBL] [Abstract][Full Text] [Related]
26. Comparative efficacy of patient-controlled administration of morphine, hydromorphone, or sufentanil for the treatment of oral mucositis pain following bone marrow transplantation.
Coda BA; O'Sullivan B; Donaldson G; Bohl S; Chapman CR; Shen DD
Pain; 1997 Sep; 72(3):333-46. PubMed ID: 9313274
[TBL] [Abstract][Full Text] [Related]
27. Subcutaneous fentanyl and sufentanil infusion substitution for morphine intolerance in cancer pain management.
Paix A; Coleman A; Lees J; Grigson J; Brooksbank M; Thorne D; Ashby M
Pain; 1995 Nov; 63(2):263-269. PubMed ID: 8628593
[TBL] [Abstract][Full Text] [Related]
28. A comparison of the resources used in advanced cancer care between two different strong opioids: an analysis of naturalistic practice in the UK.
Guest JF; Ruiz FJ; Russ J; Gupta RD; Mihai A; Greener M
Curr Med Res Opin; 2005 Feb; 21(2):271-80. PubMed ID: 15801998
[TBL] [Abstract][Full Text] [Related]
29. Intravenous methadone for cancer pain unrelieved by morphine and hydromorphone: clinical observations.
Manfredi PL; Borsook D; Chandler SW; Payne R
Pain; 1997 Mar; 70(1):99-101. PubMed ID: 9106815
[TBL] [Abstract][Full Text] [Related]
30. Opioid Pharmacokinetics-Pharmacodynamics: Clinical Implications in Acute Pain Management in Trauma.
MacKenzie M; Zed PJ; Ensom MH
Ann Pharmacother; 2016 Mar; 50(3):209-18. PubMed ID: 26739277
[TBL] [Abstract][Full Text] [Related]
31. [2 cases of successful symptom management at home by using opioid rotation from a fentanyl preparation to a continuous subcutaneous injection of morphine hydrochloride, at a dose less than the equivalent dose based on the conversion table].
Sato M; Miyamori T; Koyanagi J; Murase J; Saka S; Ishii N; Nishi T; Yamagishi T
Gan To Kagaku Ryoho; 2012 Dec; 39 Suppl 1():58-60. PubMed ID: 23268901
[TBL] [Abstract][Full Text] [Related]
32. Opioid use in palliative care of children and young people with cancer.
Hewitt M; Goldman A; Collins GS; Childs M; Hain R
J Pediatr; 2008 Jan; 152(1):39-44. PubMed ID: 18154896
[TBL] [Abstract][Full Text] [Related]
33. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
34. Survey of pain specialists regarding conversion of high-dose intravenous to neuraxial opioids.
Gorlin AW; Rosenfeld DM; Maloney J; Wie CS; McGarvey J; Trentman TL
J Pain Res; 2016; 9():693-700. PubMed ID: 27703394
[TBL] [Abstract][Full Text] [Related]
35. Neuroexcitatory effects of morphine and hydromorphone: evidence implicating the 3-glucuronide metabolites.
Smith MT
Clin Exp Pharmacol Physiol; 2000 Jul; 27(7):524-8. PubMed ID: 10874511
[TBL] [Abstract][Full Text] [Related]
36. Hydromorphone for cancer pain.
Li Y; Ma J; Lu G; Dou Z; Knaggs R; Xia J; Zhao S; Dong S; Yang L
Cochrane Database Syst Rev; 2021 Aug; 8(8):CD011108. PubMed ID: 34350974
[TBL] [Abstract][Full Text] [Related]
37. [A study of transdermal fentanyl in cancer pain at Aichi-Cancer Center].
Kato K; Mizaki T; Yamazaki S; Nitta M; Hasegawa M; Kamiya Y; Hosoda R
Yakugaku Zasshi; 2004 May; 124(5):287-91. PubMed ID: 15118241
[TBL] [Abstract][Full Text] [Related]
38. Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study.
Sittl R; Likar R; Nautrup BP
Clin Ther; 2005 Feb; 27(2):225-37. PubMed ID: 15811486
[TBL] [Abstract][Full Text] [Related]
39. Patient-controlled analgesia for mucositis pain in children: a three-period crossover study comparing morphine and hydromorphone.
Collins JJ; Geake J; Grier HE; Houck CS; Thaler HT; Weinstein HJ; Twum-Danso NY; Berde CB
J Pediatr; 1996 Nov; 129(5):722-8. PubMed ID: 8917240
[TBL] [Abstract][Full Text] [Related]
40. A double-blind, randomized comparative study to investigate the morphine to hydromorphone conversion ratio in Japanese cancer patients.
Inoue S; Saito Y; Tsuneto S; Aruga E; Ogata T; Uemori M
Jpn J Clin Oncol; 2018 May; 48(5):442-449. PubMed ID: 29635632
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
